

GLOBAL LIFE SCIENCES FUND

Part A - Toutes les données sont au 31 mai 2017

Stratégie axée sur la gestion d'entreprises offrant des solutions dans le secteur de la santé à travers le monde

Nous sommes convaincus de l'efficacité de la recherche fondamentale approfondie lorsqu'il s'agit d'identifier des entreprises du secteur des sciences de la vie affichant une décote importante par rapport à leur valeur intrinsèque. Nous nous distinguons de nos concurrents grâce à la qualité de notre équipe de gestion, à notre recherche approfondie et à notre approche rigoureuse visant à générer une solide performance ajustée du risque à long terme pour nos clients.


Performance annualisée (%)

	1 an	3 ans	5 ans	10 ans	2016	2015	2014	2013	2012	Depuis création	
										A\$acc	A€acc (hgd)
A\$acc cat. de part	6,27	8,24	18,38	10,25	-13,79	5,69	32,75	52,45	22,47	6,21	-
A€acc (hgd) cat. de part	3,99	7,23	17,46	9,37	-15,20	5,45	32,63	51,79	21,62	-	6,10
Indice	7,78	6,95	15,68	8,01	-6,81	6,60	18,10	36,27	17,54	6,90	5,90
Moyenne de la catégorie A\$acc	6,89	6,03	14,26	6,63	-10,00	5,30	17,90	34,42	17,63	6,21	-
Classement en percentile A\$acc	54	21	8	4	78	46	2	7	14	-	-

Performances cumulées (%)

	1 mois	3 mois	YTD	1 an	3 ans	5 ans	10 ans	Depuis création	
								A\$acc	A€acc (hgd)
A\$acc cat. de part	0,18	2,59	13,34	6,27	26,83	132,48	165,38	181,30	-
A€acc (hgd) cat. de part	0,00	1,99	12,31	3,99	23,28	123,62	144,82	-	176,40
Indice	2,18	4,44	12,90	7,78	22,35	107,17	116,17	214,58	167,69
Classement en percentile A\$acc	64	62	36	54	21	8	4	-	-

Performances cumulées sur 5 ans (ou depuis le lancement) (%)



La performance passée n'est pas le gage de la performance future. Source: Morningstar.

Copyright © 2017 Morningstar UK Limited. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. No Morningstar rating is shown if the fund is less than three years old or rating is below 3 stars.

En bref

- Une approche globale envers les entreprises qui répondent à des besoins médicaux non satisfaits et qui proposent des solutions efficaces et rentables dans le domaine de la santé.
- Une recherche fondamentale innovante : notre volonté est de comprendre les aspects scientifiques et économiques.
- Nous procédons à une analyse rigoureuse des valorisations et à une diversification en termes de secteur, de région géographique et de capitalisation boursière.

Risques principaux

- Risque d'investissement
- Risque lié au secteur industriel
- Concentration des risques
- Risque lié aux valeurs de petite capitalisation
- Risque lié aux IDE

Fiche de renseignement⁴

Gérant de portefeuille	Andy Acker, CFA; Ethan Lovell
Gérant depuis	1 May 07; 12 Jan 16
Devise de référence	USD
Domicile	Irlande
Indice de référence	MSCI World/Health Care NR
Catégorie	Sector Equity Healthcare
Actif net (m USD)	\$1845,3
(m EUR)	€1641,1
Négociation	Quotidien

	A\$acc	A€acc (hgd)
Lancement	31 Mar 2000	31 Mar 2000
VL	\$28,13	€27,64
ISIN	IE0009355771	IE0002122038
SEDOL	0588595	0576545
Bloomberg	JANGLA1	JAGLA1E
Classement	★★★★★	★★★★★
Morningstar		
Valoren	1060639	1060678

Caractéristiques de risque vs indice[†]

	A\$acc	Indice
Alpha	-0,03	-
Bêta	1,27	-
R2	83,06	-
Volatilité	16,96	12,19
Tracking error	7,71	-
Ratio de Sharpe	0,54	0,59
Ratio d'information	0,17	-

Caractéristiques du compartiment[‡]

Nombre de lignes	95
Taux de rotation du portefeuille	55,02%
Capitalisation boursière (moyenne pondérée) (mds USD)	\$51,2
(mds EUR)	€45,5
Capitalisation boursière médiane (mds USD)	\$5,9
(mds EUR)	€5,2
Active share	63,40

[†]Source: Morningstar. Three years trailing using Citigroup 3-month T-Bill as the risk free rate.

[‡]Source Janus Henderson Investors.

A short-term trading fee may be applied upon exiting the fund as per the prospectus.

10 premières positions (%)

Eli Lilly & Co	3,6
AstraZeneca PLC	3,1
Sanofi	3,1
Aetna Inc	3,0
Regeneron Pharmaceuticals Inc	3,0
Shire PLC (ADR)	3,0
Celgene Corp	2,8
Allergan PLC	2,3
Anthem Inc	2,2
Amgen Inc	2,2
Total	28,2

Répartition par secteur (%)

Biotechnologie	33,01
Produits pharmaceutiques	27,11
Équipement de soins de santé	14,13
Soins de santé géré	7,26
Outils/services aux sciences biologiques	3,66
Services de soins de santé	3,20
Établissements de soins de santé	2,54
Fournitures de soins de santé	2,26
Technologie médicale	1,99
Distributeurs de soins de santé	1,76

Répartition par pays principaux (%)

États-Unis	77,44
Royaume-Uni	7,45
Suisse	5,02
France	4,50
Japon	1,29
Danemark	1,25
Allemagne	0,98
Canada	0,42

Capitalisation boursière (en % du capital)

Over \$100B	15,95
\$50B to \$100B	20,88
\$10B to \$50B	26,56
\$5B to \$10B	11,24
\$1B to \$5B	18,15
\$500M to \$1B	3,00
\$250M to \$500M	0,86
Under \$100M	0,15
S/O	1,18

Allocation d'actifs (%)

Actions	97,96
Actions US	77,02
Actions non-US	20,94
Obligations	0,38
Convertibles	0,38
Espèces/quasi espèces	1,62

Source Janus Henderson Investors

Informations importantes

Note to all readers: All content in this document is for information or general use only and is not specific to any individual client requirements. The information contained in this document is referential and may not be construed as an offer, invitation or recommendation, nor should be taken as a basis to take (or stop taking) any decision. Janus Capital International Limited ("JCIL") is an entity registered and operating under the laws of the United Kingdom and Janus Capital Funds plc. is registered under the legislation of Ireland. Janus Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. Past performance is not indicative of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. This is not a solicitation for the sale of shares and nothing herein is intended to amount to investment advice. This document does not constitute investment advice or an offer to sell, buy or a recommendation for securities, other than pursuant to an agreement in compliance with applicable laws, rules and regulations. Janus Henderson Group PLC and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this document and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. As with all investments, there are inherent risks that each individual should address. The distribution of this document or the information contained in it may be restricted by law and may not be used in any jurisdiction or any circumstances in which its use would be unlawful. Note to Europe Readers: Issued in Europe by Janus Capital International Limited ("JCIL"), authorised and regulated by the U.K. Financial Conduct Authority. PROVIDED IN BAHRAIN, ABU DHABI, DUBAI, JORDAN, KAZAKHSTAN, KUWAIT, UAE, OMAN AND SAUDI ARABIA UPON CLIENT REQUEST FOR RESEARCH PURPOSES ONLY. NOT FOR ONWARD DISTRIBUTION. Note to Middle East: JCIL is regulated by the Dubai Financial Services Authority as a Representative Office. JCIL is authorised and regulated by the U.K. Financial Conduct Authority. The Janus Capital Funds will be offered and provided by JCIL on a cross-border basis from the United Kingdom only; and Janus Capital Funds plc. is registered under the legislation of Ireland and will not be and are not intended to be registered or publically offered in or from the territory of Bahrain, Botswana, Abu Dhabi, Dubai, UAE, Jordan, the Republic of Kazakhstan, Kuwait (in accordance with Decree Law No. 31 of 1990 and the implementing regulations thereto (as amended) and Law No. 7 of 2010 and the bylaws thereto (as amended)), the United Arab Emirates (including the Dubai International Financial Centre) or the Sultanate of Oman as contemplated by the Commercial Companies Law of Oman (Royal Decree 4/74) or the Capital Market Law of Oman (Royal Decree 80/98), nor does it constitute an offer to sell, or the solicitation of any offer to buy Non-Omani securities in the Sultanate of Oman as contemplated by Article 139 of the Executive Regulations to the Capital Market Law (issued by Decision No.1/2009). No transactions will be concluded in the Middle East and any enquiries should be made to JCIL. This document and the Fund that it relates to, has not been approved by or filed with the Central Bank of Bahrain, Regulatory Authority of Botswana, Qatar Central Bank, Saudi Arabian Capital Market Authority, UAE Central Bank, the UAE Securities and Commodities Authority or Dubai Financial Services Authority. Jordanian Securities Commission or the Board for Regulating Transactions in Foreign Exchanges or any other relevant licensing authorities or governmental agencies in the Middle East. Note to UAE Readers: The Units are only being offered to a limited number of sophisticated investors in the UAE who (a) are willing and able to conduct an independent investigation of the risks involved in an investment in such Units, and (b) upon their specific request by an entity whose main object or purpose, or one of its objects, is to invest in securities and its investment in the Units would be for its own account and not for the account of its clients or (c) an investment manager with authority to make and execute investment decisions. Note to Saudi Arabia: The interests may only be offered and sold in the Kingdom of Saudi Arabia in accordance with Article 4 of the Investment Funds Regulations issued on December 24, 2006 (the "Regulations"). Article 4(b)(1)/(4) of the Regulations states that, if investment fund units are offered to [no more than 200 offerees in the Kingdom of Saudi Arabia/certain persons specified in the Regulations]* and the minimum amount payable per offeree is not less than Saudi Riyals 1 million or an equivalent amount in another currency, such offer of investment fund units shall be deemed a private placement for purposes of the Regulations. Investors are informed that Article 4(g) of the Regulations places restrictions on secondary market activity with respect to such investment fund units. This presentation is strictly private and confidential and may not be reproduced or used for any purpose other than evaluation of a potential investment in Janus Capital International Limited's products or the procurement of its services by the recipient of this presentation or provided to any person or entity other than the recipient of this presentation. Janus Capital Management LLC serves as investment adviser. Janus, INTECH and Perkins are registered trademarks of Janus International Holding LLC. © Janus International Holding LLC. For more information or to locate your country's Janus Henderson Investors representative contact information, please visit www.janushenderson.com. Effective 12th January 2016 Eithan Lovell was promoted to Co-Portfolio Manager of the Janus Global Life Sciences Fund and affiliated accounts, joining Andy Acker, who was previously sole manager of the Fund. Due to the concentrated nature of these strategies, performance could be impacted more by movements in any one holding than a diversified strategy would be. This means that the strategies performances are likely to fluctuate more than a diversified strategy would. The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd ("FIFS"), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: <http://www.fifs.ch>. The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l'Île, CH-1204 Geneva. The last share prices can be found on www.fundinfo.com. The head office is registered Janus Henderson Group PLC (reg. no. 126509), 201 Bishopsgate, London EC2M 3AE, United Kingdom. Outside of Switzerland, this document is for Institutional/sophisticated investors / accredited investors qualified distributors use only. JS-0816(40-T)0817 EM Inst

En savoir plus

FR: +33 1 53 05 44 80

info.france@janushenderson.comwww.janushenderson.com

ou contactez votre représentant habituel de Janus Henderson Investor.